T. Rowe Price Associates
OREX

T. Rowe Price Associates’s Orexigen Therapeutics, Inc. OREX Stock Holding History

T. Rowe Price Associates’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-650,842
Closed -$11.2M – 2592
2015
Q4 		$11.2M Buy
650,842
+1,670
+0.3% +$39.8K ﹤0.01% 1259
2015
Q3 		$13.7M Sell
649,172
-9,198
-1% -$315K ﹤0.01% 1224
2015
Q2 		$32.6M Sell
658,370
-2,910
-0.4% -$174K 0.01% 983
2015
Q1 		$51.8M Sell
661,280
-5,240
-0.8% -$325K 0.01% 834
2014
Q4 		$40.4M Sell
666,520
-148,000
-18% -$7.43M 0.01% 907
2014
Q3 		$34.7M Buy
814,520
+335,880
+70% +$18M 0.01% 950
2014
Q2 		$29.6M Buy
478,640
+215,189
+82% +$12.5M 0.01% 1015
2014
Q1 		$17.1M Buy
263,451
+258,991
+5,807% +$17.5M ﹤0.01% 1154
2013
Q4 		$251K Buy
4,460
+2,980
+201% +$167K ﹤0.01% 2228
2013
Q3 		$91K Sell
1,480
-85,090
-98% -$5.76M ﹤0.01% 2395
2013
Q2 		$5.06M Buy
+86,570
New +$5.33M ﹤0.01% 1405

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates's OREX Position: Q1 2016 in Review

T. Rowe Price Associates sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 650,842 shares — an estimated $11.2M sold.

T. Rowe Price Associates first reported a position in OREX in Q2 2013 and held it in 11 quarters. The position peaked at $51.8M in Q1 2015. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • T. Rowe Price Associates reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • T. Rowe Price Associates sold 650,842 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $11.2M.
  • T. Rowe Price Associates first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
  • T. Rowe Price Associates's Orexigen Therapeutics, Inc. position peaked at $51.8M in Q1 2015.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on T. Rowe Price Associates's 13F filing for Q1 2016, filed 16 May 2016.